Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization

被引:43
|
作者
Wang, Kai [1 ]
Chen, Qinhua [2 ]
Liu, Nanxin [1 ]
Zhang, Jie [1 ]
Pan, Xiaoyan [1 ]
机构
[1] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Pharm, Xian 710061, Peoples R China
[2] Shenzhen Baoan Authent TCM Therapy Hosp, Dept Pharm, Shenzhen 518101, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
Drug resistance; Tumor angiogenesis; Vascular normalization; Anti-angiogenesis inhibitors; Multiplex inhibitors; CANCER; OXYGENATION; METASTASIS; INHIBITION; VEGFR2; DESIGN; TARGET; PFKFB3;
D O I
10.1016/j.drudis.2021.07.024
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A major problem associated with cancer treatment is resistance-prone chemotherapeutic drugs. An increasing number of studies have documented that the occurrence of resistance tends to be associated with abnormal blood vessels. In 2001, Jain proposed the vascular normalization theory, which was recently applied to the drug-resistant treatment of tumors in the clinic. Through the intervention of angiogenesis inhibitors, remodeling the structure and function of abnormal vessels can maximize the efficacy of chemotherapeutic drugs. In this review, we systematically describe the occurrence and progress of tumor angiogenesis, as well as the pathological characteristics of tumor blood vessels. Moreover, druggable targets for vascular normalization and the development of related inhibitors are also outlined.
引用
收藏
页码:2743 / 2753
页数:11
相关论文
共 50 条
  • [31] ANTI-ANGIOGENESIS ACTIVITY OF THE DESMOPLASTIC RESPONSE TO TUMOR INVASION
    NELSON, L
    LEVY, V
    BARSKY, S
    MODERN PATHOLOGY, 1988, 1 (01) : A66 - A66
  • [32] ANTI-ANGIOGENESIS ACTIVITY OF THE DESMOPLASTIC RESPONSE TO TUMOR INVASION
    NELSON, L
    LEVY, V
    BARSKY, S
    LABORATORY INVESTIGATION, 1988, 58 (01) : A66 - A66
  • [33] Tumor-Specific Delivery of Histidine-Rich Glycoprotein Suppresses Tumor Growth and Metastasis by Anti-angiogenesis and Vessel Normalization
    Cheng, Xiawei
    Zhang, Xiaoxin
    Cheng, Wei
    Chen, Jianxiang
    Ma, Cailie
    Yang, Bingya
    Hua, Zi-Chun
    CURRENT GENE THERAPY, 2014, 14 (02) : 75 - 85
  • [34] Anti-angiogenesis: making the tumor vulnerable to the immune system
    Griffioen, Arjan W.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (10) : 1553 - 1558
  • [35] Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor
    Li, Xiaoyu
    Wu, Meiying
    Pan, Limin
    Shi, Jianlin
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2016, 11 : 93 - 105
  • [36] CONTROLLING THE VASCULATURE - ANGIOGENESIS, ANTI-ANGIOGENESIS AND VASCULAR TARGETING OF GENE-THERAPY
    FAN, TPD
    JAGGAR, R
    BICKNELL, R
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1995, 16 (02) : 57 - 66
  • [37] Anti-Angiogenesis and Anti-Tumor Effect of Shark Cartilage Extract
    王锋
    王漪涛
    谢莉萍
    张荣庆
    TsinghuaScienceandTechnology, 2001, (03) : 200 - 205
  • [38] New paradigms for the treatment of cancer: The role of anti-angiogenesis agents
    Cherrington, JM
    Strawn, LM
    Shawver, LK
    ADVANCES IN CANCER RESEARCH, VOL 79, 2000, 79 : 1 - 38
  • [39] Antiresorptive Agents and Anti-Angiogenesis Drugs in the Development of Osteonecrosis of the Jaw
    Allegra, Alessandro
    Innao, Vanessa
    Pulvirenti, Nicolina
    Musolino, Caterina
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2019, 248 (01): : 27 - 29
  • [40] Angioprevention:: Anti-angiogenesis as a critical target for cancer chemopreventive agents
    Pfeffer, U
    Tosetti, F
    Ferrari, N
    Venè, R
    Benelli, R
    Morini, M
    Garbisa, S
    Noonan, D
    Albini, A
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2002, 11 (10) : 1235S - 1235S